Next Article in Journal
Advancements in the Treatment Landscape of Hepatocellular Carcinoma
Previous Article in Journal
Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 16
Issue 5
10.3390/cancers16051053
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

Chimeric Antigen Receptor-Modified T Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer: Promise and Potential

by
Leah R. Tharian
1,
Shiv Verma
2,3 and
Sanjay Gupta
2,3,4,5,6,7,*
1
College of Arts and Sciences, Case Western Reserve University, Cleveland, OH 44016, USA
2
Department of Urology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
3
The Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA
4
Department of Pharmacology, Case Western Reserve University, Cleveland, OH 44016, USA
5
Department of Pathology, Case Western Reserve University, Cleveland, OH 44016, USA
6
Department of Nutrition, Case Western Reserve University, Cleveland, OH 44016, USA
7
Division of General Medical Sciences, Case Comprehensive Cancer Center, Cleveland, OH 44106, USA
*
Author to whom correspondence should be addressed.
Cancers 2024, 16(5), 1053; https://doi.org/10.3390/cancers16051053
Submission received: 20 February 2024 / Accepted: 28 February 2024 / Published: 5 March 2024
(This article belongs to the Section Tumor Microenvironment)
Versions Notes

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

Prostate cancer, the most common cancer among males, has a mortality rate of approximately 29,000 deaths each year in the United States alone [...]

Share and Cite

MDPI and ACS Style

Tharian, L.R.; Verma, S.; Gupta, S. Chimeric Antigen Receptor-Modified T Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer: Promise and Potential. Cancers 2024, 16, 1053. https://doi.org/10.3390/cancers16051053

AMA Style

Tharian LR, Verma S, Gupta S. Chimeric Antigen Receptor-Modified T Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer: Promise and Potential. Cancers. 2024; 16(5):1053. https://doi.org/10.3390/cancers16051053

Chicago/Turabian Style

Tharian, Leah R., Shiv Verma, and Sanjay Gupta. 2024. "Chimeric Antigen Receptor-Modified T Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer: Promise and Potential" Cancers 16, no. 5: 1053. https://doi.org/10.3390/cancers16051053

APA Style

Tharian, L. R., Verma, S., & Gupta, S. (2024). Chimeric Antigen Receptor-Modified T Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer: Promise and Potential. Cancers, 16(5), 1053. https://doi.org/10.3390/cancers16051053

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop